WuXi Biologics (Cayman) Inc.

DB:1FW2 Stock Report

Market Cap: €12.8b

WuXi Biologics (Cayman) Valuation

Is 1FW2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1FW2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€5.45
Fair Value
42.9% undervalued intrinsic discount
26
Number of Analysts

Below Fair Value: 1FW2 (€3.11) is trading below our estimate of fair value (€5.45)

Significantly Below Fair Value: 1FW2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1FW2?

Key metric: As 1FW2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1FW2. This is calculated by dividing 1FW2's market cap by their current earnings.
What is 1FW2's PE Ratio?
PE Ratio38.3x
EarningsCN¥2.63b
Market CapCN¥100.69b

Price to Earnings Ratio vs Peers

How does 1FW2's PE Ratio compare to its peers?

The above table shows the PE ratio for 1FW2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average66.7x
SRT3 Sartorius
192.2x27.8%€14.4b
1SXP SCHOTT Pharma KGaA
26.3x14.8%€3.5b
GXI Gerresheimer
24x18.5%€2.6b
MEDP Medpace Holdings
24.4x9.5%US$9.9b
1FW2 WuXi Biologics (Cayman)
38.3x16.5%€108.0b

Price-To-Earnings vs Peers: 1FW2 is good value based on its Price-To-Earnings Ratio (38.3x) compared to the peer average (66.7x).

Price to Earnings Ratio vs Industry

How does 1FW2's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
1FW2 38.3xIndustry Avg. 30.8xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1FW2 is expensive based on its Price-To-Earnings Ratio (38.3x) compared to the European Life Sciences industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 1FW2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1FW2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.3x
Fair PE Ratio24.4x

Price-To-Earnings vs Fair Ratio: 1FW2 is expensive based on its Price-To-Earnings Ratio (38.3x) compared to the estimated Fair Price-To-Earnings Ratio (24.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1FW2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.11
€2.67
-14.3%
29.9%€4.16€1.16n/a26
Mar ’26€2.68
€2.76
+3.1%
30.5%€4.31€1.20n/a25
Feb ’26€2.36
€2.59
+9.8%
31.0%€4.34€1.21n/a25
Jan ’26€2.17
€2.41
+11.0%
37.0%€4.21€1.20n/a24
Dec ’25€1.84
€2.30
+24.8%
38.7%€4.19€1.20n/a25
Nov ’25€1.95
€2.31
+18.7%
39.8%€4.16€1.19n/a26
Oct ’25€2.05
€2.26
+10.4%
43.8%€4.91€1.17n/a26
Sep ’25€1.29
€2.23
+73.0%
44.8%€4.88€0.99n/a26
Aug ’25€1.33
€2.52
+89.7%
38.5%€4.97€1.01n/a25
Jul ’25€1.36
€2.70
+97.9%
44.9%€6.34€1.42n/a25
Jun ’25€1.33
€3.12
+133.6%
58.2%€8.62€1.41n/a26
May ’25€1.65
€3.41
+106.1%
55.3%€8.75€1.43n/a26
Apr ’25€1.67
€4.12
+147.1%
53.2%€8.74€1.43n/a28
Mar ’25€2.19
€6.07
+176.8%
33.9%€13.87€2.59€2.6829
Feb ’25€2.46
€6.06
+146.6%
33.9%€13.80€2.58€2.3629
Jan ’25€3.36
€6.18
+84.1%
34.6%€13.72€2.56€2.1729
Dec ’24€5.04
€8.92
+77.0%
19.9%€13.83€5.61€1.8427
Nov ’24€5.73
€8.98
+56.7%
19.6%€13.64€5.65€1.9527
Oct ’24€5.46
€9.35
+71.2%
23.8%€16.38€5.66€2.0529
Sep ’24€5.27
€9.38
+78.1%
23.2%€16.17€5.59€1.2929
Aug ’24€5.16
€9.47
+83.7%
24.6%€16.04€3.49€1.3329
Jul ’24€4.37
€9.56
+118.9%
23.5%€15.97€3.48€1.3629
Jun ’24€5.01
€10.35
+106.8%
17.5%€16.56€7.96€1.3329
May ’24€5.49
€10.33
+88.3%
17.5%€16.60€7.98€1.6529
Apr ’24€5.64
€10.56
+87.3%
17.5%€16.98€8.16€1.6729
Mar ’24€6.99
€12.08
+72.8%
24.7%€23.70€8.30€2.1928
Analyst Price Target
Consensus Narrative from 26 Analysts
€2.68
Fair Value
16.3% overvalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 11:42
End of Day Share Price 2025/03/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Jian Xiong LimCFRA Equity Research